PMID- 23045581
OWN - NLM
STAT- MEDLINE
DCOM- 20130306
LR  - 20211021
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 30
IP  - 33
DP  - 2012 Nov 20
TI  - HIV status does not influence outcome in patients with classical Hodgkin lymphoma 
      treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and 
      dacarbazine in the highly active antiretroviral therapy era.
PG  - 4111-6
LID - 10.1200/JCO.2011.41.4193 [doi]
AB  - PURPOSE: The prognosis of HIV-infected patients with non-Hodgkin lymphoma in the 
      highly active antiretroviral therapy (HAART) era approaches that of the general 
      population when they are treated with the same protocols. We analyzed the outcome 
      of patients with Hodgkin lymphoma (HL) treated with doxorubicin, bleomycin, 
      vinblastine, and dacarbazine (ABVD) in the HAART era according to HIV serostatus 
      to establish whether this also holds true for HL. PATIENTS AND METHODS: From 1997 
      to 2010, 224 patients newly diagnosed with HL, of whom 93 were HIV positive, were 
      consecutively treated with ABVD chemotherapy. HIV-positive patients had more 
      high-risk disease according to the International Prognostic Score (IPS) than 
      HIV-negative patients (IPS>/=3: 68% v 26%, respectively; P<.001). Forty-seven 
      HIV-positive patients had a CD4 count less than 200/muL, and 92 patients received 
      HAART during chemotherapy. RESULTS: The complete response rate was 74% for 
      HIV-positive patients and 79% for HIV-negative patients (P=not significant). 
      After a median follow-up of 60 months (range, 8 to 174 months), 23 patients (16 
      HIV-negative and seven HIV-positive patients) have experienced relapse at a 
      median time of 6 months (range, 1 to 106 months). Five-year event-free survival 
      (EFS) was 59% (95% CI, 47% to 70%) for HIV-positive patients and 66% (95% CI, 57% 
      to 74%) for HIV-negative patients (P=not significant). Five-year overall survival 
      (OS) was 81% (95% CI, 69% to 89%) and 88% (95% CI, 80% to 93%) for HIV-positive 
      and HIV-negative patients, respectively (P=not significant). HIV status did not 
      predict OS or EFS on multivariate analysis including IPS and HIV status. 
      CONCLUSION: This mature study demonstrates that HIV-positive patients with HL 
      have more extensive disease with more adverse prognostic factors than 
      HIV-negative patients, but when treated with ABVD, HIV infection does not 
      adversely affect OS or EFS.
FAU - Montoto, Silvia
AU  - Montoto S
AD  - Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of 
      London, Chelsea and Westminster Hospital, 45 Little Britain, EC1A 7BE, London, 
      United Kingdom. s.montoto@qmul.ac.uk
FAU - Shaw, Kate
AU  - Shaw K
FAU - Okosun, Jessica
AU  - Okosun J
FAU - Gandhi, Shreyans
AU  - Gandhi S
FAU - Fields, Paul
AU  - Fields P
FAU - Wilson, Andrew
AU  - Wilson A
FAU - Shanyinde, Milensu
AU  - Shanyinde M
FAU - Cwynarski, Kate
AU  - Cwynarski K
FAU - Marcus, Robert
AU  - Marcus R
FAU - de Vos, Johannes
AU  - de Vos J
FAU - Young, Anna Marie
AU  - Young AM
FAU - Tenant-Flowers, Melinda
AU  - Tenant-Flowers M
FAU - Orkin, Chloe
AU  - Orkin C
FAU - Johnson, Margaret
AU  - Johnson M
FAU - Chilton, Daniella
AU  - Chilton D
FAU - Gribben, John G
AU  - Gribben JG
FAU - Bower, Mark
AU  - Bower M
LA  - eng
GR  - P01 CA081534/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121008
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 11056-06-7 (Bleomycin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - ABVD protocol
SB  - IM
CIN - J Clin Oncol. 2012 Nov 20;30(33):4056-8. PMID: 23045587
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Antiretroviral Therapy, Highly Active/adverse effects/*methods
MH  - Bleomycin/administration & dosage/adverse effects
MH  - Dacarbazine/administration & dosage/adverse effects
MH  - Disease-Free Survival
MH  - Doxorubicin/administration & dosage/adverse effects
MH  - Female
MH  - HIV Infections/*complications/*drug therapy
MH  - Hodgkin Disease/*drug therapy/pathology/*virology
MH  - Humans
MH  - Lymphoma, AIDS-Related/*drug therapy/pathology/virology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Vinblastine/administration & dosage/adverse effects
MH  - Young Adult
PMC - PMC5320889
COIS- Authors' disclosures of potential conflicts of interest and author contributions 
      are found at the end of this article.
EDAT- 2012/10/10 06:00
MHDA- 2013/03/07 06:00
PMCR- 2012/10/08
CRDT- 2012/10/10 06:00
PHST- 2012/10/10 06:00 [entrez]
PHST- 2012/10/10 06:00 [pubmed]
PHST- 2013/03/07 06:00 [medline]
PHST- 2012/10/08 00:00 [pmc-release]
AID - JCO.2011.41.4193 [pii]
AID - 14193 [pii]
AID - 10.1200/JCO.2011.41.4193 [doi]
PST - ppublish
SO  - J Clin Oncol. 2012 Nov 20;30(33):4111-6. doi: 10.1200/JCO.2011.41.4193. Epub 2012 
      Oct 8.